BrainsWay · FDA-Cleared

The faster path to
depression remission.

SWIFT™ Accelerated Deep TMS protocol compresses the acute treatment phase to just 6 half days — delivering comparable efficacy to standard protocol with a fraction of the time commitment.
87.8%
Response Rate
78.0%
Remission Rate
21 days
Median Time to Remission
FDA-Cleared Accelerated Protocol No fMRI Required Peer-Reviewed No Neuroimaging

See SWIFT in action.

Request a demo or speak with a clinical specialist about adding SWIFT to your practice.

A BrainsWay specialist will follow up within 1 business day.

The Protocol

Acute relief in
6 half days.

SWIFT uses a 10-minute iTBS protocol targeting the Central Executive Network via the H1 Coil. The acute phase is followed by a brief continuation phase — total treatment is complete in 6 weeks.


Short-Course With Intrinsic Field Targeting — no fMRI neuronavigation required, unlike competing accelerated protocols.

Acute Phase · 6 visits within 2 weeks
Day 15×
Day 25×
Day 35×
Day 45×
Day 55×
Day 65×
Min. 50 min between sessions · 10-min iTBS each
30acute treatments
Continuation Phase · Weeks 3–6
Week 32×
Week 42×
Week 52×
Week 62×
Same-day sessions · 1 visit/week
8continuation treatments
6
SWIFT acute visits
vs.
20
Standard acute visits
→
70%
Fewer visits
Clinical Outcomes

Comparable efficacy.
Significantly faster.

Published in Brain Stimulation, a large multicenter randomized non-inferiority trial confirmed SWIFT achieves outcomes on par with standard daily protocol — with a faster median time to remission.

87.8%

Response rate in the SWIFT protocol arm — matching the 87.5% achieved under standard daily protocol.

Brain Stimulation, 2026 · HDRS-21
78.0%

Remission rate, defined as HDRS-21 < 10, consistent across patients with moderate-to-severe depression and comorbid anxiety.

Brain Stimulation, 2026 · HDRS-21
21 days

Median time to remission for SWIFT — one week faster than the 28-day median under the standard protocol.

vs. 28 days standard · p=0.0324
~70%

Of SWIFT patients no longer suffered from severe quality of life impairment by end of treatment.

Patient-reported outcomes manuscript
~60%

Of patients returned to normal-range functioning. Quality-of-life scores improved by approximately 32 percentage points from baseline — with patients reporting reconnection to work, relationships, and daily routines.

Patient-reported outcomes manuscript · 6-week endpoint
🧠

No fMRI. No neuronavigation. No friction.

Unlike similar protocols, SWIFT requires no fMRI-guided neuronavigation — making it immediately practical and cost-effective for outpatient psychiatric practices without adding imaging infrastructure or referral steps.

“SWIFT demonstrates that we can substantially reduce treatment burden without compromising on outcomes, which fundamentally changes what access looks like for patients.”
Colleen A. Hanlon, Ph.D. · Vice President of Medical Affairs, BrainsWay

Study published March 2026
Two peer-reviewed manuscripts in Brain Stimulation from a multisite, randomized non-inferiority trial incorporating input from patients and providers in both urban and rural settings.

Brain Stimulation Journal Randomized Trial Multisite Non-Inferiority Urban + Rural

Ready to bring SWIFT
to your practice?

Connect with a BrainsWay clinical specialist to review the data, explore workflow integration, and get pricing tailored to your practice volume. Most clinics are operational within weeks.

✓ FDA-Cleared ✓ No fMRI Needed ✓ Peer-Reviewed Data

Request a Consultation

We'll follow up within 1 business day.